Fig. 1: Schematic diagram and study design of HER2 + mBC patients. | Cell Death Discovery

Fig. 1: Schematic diagram and study design of HER2 + mBC patients.

From: A long noncoding RNA-based serum signature predicts ado-trastuzumab emtansine (T-DM1) treatment benefit in HER2+ metastatic breast cancer patients: a multicenter cohort study

Fig. 1

The datasets are primary samples that were obtained at the time of diagnosis and are classified as follows: A training cohort (blue), B internal cohort (red), C independent cohort (purple), and D chemotherapy-only cohort (orange-red). Microarray data generated from (A). E Study design for the training cohort and two validation cohorts (internal and independent cohorts) for lncRNA signature discovery and functional analysis of the lncRNA signature. Patients who achieved CR, PR, or SD for more than 6 months were defined as sensitive to T-DM1. PD or SD prolonged to less than 6 months was defined as resistance to T-DM1. CR complete response, PR partial response, SD stable disease, PD progressive disease.

Back to article page